

2016

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.

Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman S, Cooley S, *et al*
Cancer Res. 2016 Oct;76(19):5696-5706

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Meeks H, Song H, Michailidou K, Bolla M, Dennis J, Wang Q, *et al*
J. Natl. Cancer Inst. 2016 Feb;108(2):

A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Sooriakumaran P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, *et al*
Eur. Urol. 2016 May;69(5):788-94

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, *et al*
Nat Commun 2016 Sep;7():12675

Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis.

Lourda M, Olsson-Åkefeldt S, Gavhed D, Axdorph Nygell U, Berlin G, Laurencikas E, *et al*
Blood 2016 Sep;128(9):1302-5

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.

Lalonde E, Alkallas R, Chua M, Fraser M, Haider S, Meng A, *et al*
Eur. Urol. 2016 Nov;():

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra M, *et al*
Ann. Oncol. 2016 Sep;27(suppl 5):v1-v27

Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent.

Guo Y, Warren Andersen S, Shu X, Michailidou K, Bolla M, Wang Q, *et al*
PLoS Med. 2016 Aug;13(8):e1002105

Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue.

Aakula A, Kohonen P, Leivonen S, Mäkelä R, Hintsanen P, Mpindi J, *et al*
Eur. Urol. 2016 Jun;69(6):1120-8


Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

De Ruyscher D, Lueza B, Le Péchoux C, Johnson D, O'Brien M, Murray N, *et al*
Ann. Oncol. 2016 Oct;27(10):1818-28

Splicing controls the ubiquitin response during DNA double-strand break repair.

Pederiva C, Böhm S, Julner A, Farnebo M
Cell Death Differ. 2016 Oct;23(10):1648-57

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA).

Tandstad T, Ståhl O, Dahl O, Haugnes H, Håkansson U, Karlsdottir , et al
Ann. Oncol. 2016 Jul;27(7):1299-304

Screening out irrelevant cell-based models of disease.

Horvath P, Aulner N, Bickle M, Davies A, Nery E, Ebner D, et al
Nat Rev Drug Discov 2016 11;15(11):751-769

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F, Carles J, Gillissen S, Heidenreich A, Heinrich D, Gratt J, et al
Lancet Oncol. 2016 Sep;17(9):1306-16


Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

Schmidt M, Hogervorst F, van Hien R, Cornelissen S, Broeks A, Adank M, et al
J. Clin. Oncol. 2016 Aug;34(23):2750-60

Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression.

Ivanov M, Kals M, Lauschke V, Barragan I, Ewels P, Käller M, et al
Nucleic Acids Res. 2016 Aug;44(14):6756-69

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.

Parker C, Finkelstein S, Michalski J, O'Sullivan J, Bruland , Vogelzang N, et al
Eur. Urol. 2016 Nov;70(5):875-883

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.

Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, et al
EMBO J. 2016 Oct;35(20):2192-2212

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.

Ghousaini M, French J, Michailidou K, Nord S, Beesley J, Canisus S, et al
Am. J. Hum. Genet. 2016 Oct;99(4):903-911

Identification of characteristic and prognostic values of chromosome 1p abnormality by multi-gene fluorescence in situ hybridization in multiple myeloma.

Li F, Hu L, Xu Y, Li Z, Yi S, Gu Z, et al
Leukemia 2016 May;30(5):1197-201

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.

Buchli C, Martling A, Abani M, Frödin J, Bottai M, Lax I, *et al*
Ann. Surg. 2016 Nov;():

Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth.

Gerling M, Büller N, Kirn L, Joost S, Frings O, Englert B, *et al*
Nat Commun 2016 Aug;7():12321

Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.

Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, *et al*
Clin. Cancer Res. 2016 Jan;22(1):146-57

Understanding transport by the major facilitator superfamily (MFS): structures pave the way.

Quistgaard E, Löw C, Guettou F, Nordlund P
Nat. Rev. Mol. Cell Biol. 2016 02;17(2):123-32

The 1p36 Tumor Suppressor KIF 1B β Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.

Li S, Fell S, Surova O, Smedler E, Wallis K, Chen Z, *et al*
Dev. Cell 2016 Jan;36(2):164-78

A saposin-lipoprotein nanoparticle system for membrane proteins.

Frauenfeld J, Löving R, Armache J, Sonnen A, Guettou F, Moberg P, *et al*
Nat. Methods 2016 Apr;13(4):345-51

The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies.

Martinez Molina D, Nordlund P
Annu. Rev. Pharmacol. Toxicol. 2016 ;56():141-61

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Gadgeel S, Shaw A, Govindan R, Gandhi L, Socinski M, Camidge D, *et al*
J. Clin. Oncol. 2016 Dec;34(34):4079-4085

Consistency in drug response profiling.

Mpindi J, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, *et al*
Nature 2016 11;540(7631):E5-E6

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Foukakis T, von Minckwitz G, Bengtsson N, Brandberg Y, Wallberg B, Fornander T, *et al*
JAMA 2016 11;316(18):1888-1896

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

Helgadottir H, Höiom V, Tuominen R, Nielsen K, Jönsson G, Olsson H, *et al*
J. Natl. Cancer Inst. 2016 Nov;108(11):

Pericyte-fibroblast transition promotes tumor growth and metastasis.

Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, *et al*
Proc. Natl. Acad. Sci. U.S.A. 2016 Sep;113(38):E5618-27

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Mao Y, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, *et al*
Blood 2016 Sep;128(11):1475-89

Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype.

Shen X, Burguillos M, Osman A, Frijhoff J, Carrillo-Jiménez A, Kanatani S, *et al*
Nat. Immunol. 2016 Nov;17(11):1282-1290

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.

Tobin N, Wennmalm K, Lindström L, Foukakis T, He L, Genové G, *et al*
Clin. Cancer Res. 2016 May;22(10):2417-26

iGEMS: an integrated model for identification of alternative exon usage events.

Sood S, Szkop K, Nakhuda A, Gallagher I, Murie C, Brogan R, *et al*
Nucleic Acids Res. 2016 Jun;44(11):e109

nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.

Gandin V, Masvidal L, Hulea L, Gravel S, Cargnello M, McLaughlan S, *et al*
Genome Res. 2016 05;26(5):636-48

Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages.

Wallerius M, Wallmann T, Bartish M, Östling J, Mezheyeuski A, Tobin N, *et al*
Cancer Res. 2016 Jun;76(11):3166-78

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Lipton J, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, *et al*
Lancet Oncol. 2016 May;17(5):612-21

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.

Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, *et al*
Nat Commun 2016 Apr;7():11127

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Mao Y, Eissler N, Blanc K, Johnsen J, Kogner P, Kiessling R
Clin. Cancer Res. 2016 Aug;22(15):3849-59

Gene regulatory mechanisms underpinning prostate cancer susceptibility.

Whittington T, Gao P, Song W, Ross-Adams H, Lamb A, Yang Y, *et al*
Nat. Genet. 2016 Apr;48(4):387-97

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.

Dunning A, Michailidou K, Kuchenbaecker K, Thompson D, French J, Beesley J, *et al*
Nat. Genet. 2016 Apr;48(4):374-86

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism.

Jia M, Andreassen T, Jensen L, Bathen T, Sinha I, Gao H, *et al*
Cancer Res. 2016 Oct;76(19):5634-5646

Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?

Papakonstantinou A, Foukakis T, Rodriguez-Wallberg K, Bergh J
J. Clin. Oncol. 2016 May;34(14):1573-9

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, *et al*
Autophagy 2016;12(1):1-222.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, *et al*
Ann. Oncol. 2016 Aug;27(8):1378-81

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

O'Brien S, Jones J, Coutre S, Mato A, Hillmen P, Tam C, *et al*
Lancet Oncol. 2016 Oct;17(10):1409-1418

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, *et al*
Clin. Cancer Res. 2016 Aug;22(16):4030-8

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Epstein J, Zelefsky M, Sjoberg D, Nelson J, Egevad L, Magi-Galluzzi C, *et al*
Eur. Urol. 2016 Mar;69(3):428-35

Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?

Rodriguez-Wallberg K, Turan V, Munster P, Oktay K
Ann. Oncol. 2016 Feb;27(2):357

TAP-ing into TIEPPs for cancer immunotherapy.

Kiessling R
J. Clin. Invest. 2016 Feb;126(2):480-2

ERR α Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller L, Alayev A, Schwartz N, *et al*
Clin. Cancer Res. 2016 Mar;22(6):1421-31

The Proteome of Primary Prostate Cancer.

Iglesias-Gato D, Wikström P, Tyanova S, Lavalley C, Thysell E, Carlsson J, *et al*
Eur. Urol. 2016 May;69(5):942-52

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen A, Friesland S, *et al*
Ann. Oncol. 2016 Apr;27(4):660-7

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Ou S, Ahn J, De Petris L, Govindan R, Yang J, Hughes B, *et al*
J. Clin. Oncol. 2016 Mar;34(7):661-8

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

Couch F, Kuchenbaecker K, Michailidou K, Mendoza-Fandino G, Nord S, Lilyquist J, *et al*
Nat Commun 2016 Apr;7():11375

Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.

Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, *et al*
Hepatology 2016 Mar;63(3):898-913

Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.

Loeb S, Folkvaljon Y, Robinson D, Lissbrant I, Egevad L, Stattin P
Eur. Urol. 2016 Jun;69(6):1135-41

Validation and development of MTH1 inhibitors for treatment of cancer.

Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, *et al*
Ann. Oncol. 2016 Dec;27(12):2275-2283

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Gunnarsson N, Höglund M, Stenke L, Wållberg-Jonsson S, Sandin F, Björkholm M, *et al*
Leukemia 2016 Jul;30(7):1562-7

Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, *et al*
Ann. Intern. Med. 2016 Aug;165(3):161-6


Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.

Shukla N, Somwar R, Smith R, Ambati S, Munoz S, Merchant M, *et al*
Cancer Res. 2016 Aug;76(15):4525-34

End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study.

Ahmadi Z, Wysham N, Lundström S, Janson C, Currow D, Ekström M
Thorax 2016 Jun;71(6):510-6

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.

Hagman H, Frödin J, Berglund , Sundberg J, Vestermark L, Albertsson M, *et al*
Ann. Oncol. 2016 Jan;27(1):140-7

Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.

Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, *et al*
Blood 2016 Dec;128(23):2655-2665

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.

Gréen H, Hasmats J, Kupersmidt I, Edsgård D, de Petris L, Lewensohn R, *et al*
Clin. Cancer Res. 2016 Jan;22(2):366-73

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva R, Grosicki S, *et al*
Lancet Oncol. 2016 Feb;17(2):200-11

Utility of Reporting the Percentage of High-grade Prostate Cancer.

Egevad L, Delahunt B, Samarasingha H, Srigley J
Eur. Urol. 2016 Apr;69(4):599-600

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman R, Wilson C, Powles T, Clézardin P, Aapro M, *et al*
Ann. Oncol. 2016 Mar;27(3):379-90

CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.

Almqvist H, Axelsson H, Jafari R, Dan C, Mateus A, Haraldsson M, *et al*
Nat Commun 2016 Mar;7():11040

A 21-Gene Expression Assay in Breast Cancer.

Foukakis T, Falato C, Bergh J
N. Engl. J. Med. 2016 Apr;374(14):1386-7

Sisyphus Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.

Bergh J, Pritchard K, Cameron D
J. Clin. Oncol. 2016 Mar;34(9):895-7

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Feldman D, Lorch A, Kramar A, Albany C, Einhorn L, Giannatempo P, *et al*
J. Clin. Oncol. 2016 Feb;34(4):345-51

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.

Nilsson S, Cisko P, Sartor O, Vogelzang N, Coleman R, O'Sullivan J, *et al*
Ann. Oncol. 2016 May;27(5):868-74

Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.

Brand J, Hedayati E, Humphreys K, Ludvigsson J, Johansson A, Bergh J, *et al*
Clin. Cancer Res. 2016 Nov;22(21):5249-5255

Safety and efficacy of the combination of pegylated interferon- α 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, *et al*
Leukemia 2016 Sep;30(9):1853-60